A Phase 1/2a clinical trial of KJ-103, in selected TROP2 expressing solid tumours
Latest Information Update: 25 Oct 2024
Price :
$35 *
At a glance
- Drugs KJ 103 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 25 Oct 2024 New trial record